title: [Efficacy and toxicity of erlotinib in non-small cell lung cancer treatment].
abstract: OBJECTIVE
  To evaluate the efficacy and toxicity of erlotinib in patients with non-small cell lung cancer.
  
  
  METHODS
  Patients were selected from an outpatients' dispensing database. The time period selected was from January 2008 to January 2010. Data was collected from patient's medical history - electronic and paper based. We used Response Evaluation Criteria in Solid Tumours (RECIST) to measure response and measured time to progression and overall survival. Toxicity was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE).
  
  
  RESULTS
  We found partial response in 5/46 patients and stable disease in 14/46 patients. Time to disease progression was 4.01 months (median 2.33 months) and overall survival was 5.63 months (median 4.67). The most common toxicities were rash, anorexia, asthenia, infection and gastrointestinal side effects. Patients who developed skin toxicity had a (statistically significant) greater time to progression and overall survival rate than the group that did not develop this toxicity (mean time to progression: 2.76 vs. 7.87 months; mean overall survival: 10.74 months vs. 3.98).
  
  
  CONCLUSIONS
  Survival analysis findings suggest lower efficacy in our patient population in comparison with data seen in other publications, and adverse events followed the expected pattern. Although our greatest limitation was sample size, which must be kept in mind, this therapy could be an alternative for patients with non-small cell lung cancer.
authors.affiliation: Servicio de Farmacia, Complejo Hospitalario Universitario de Vigo, Hospital Xeral-Cíes, España. elena.yaiza.romero.ventosa2@sergas.es
authors.forename: E Y
authors.initials: EY
authors.lastname: Romero-Ventosa
authors.forename: A
authors.initials: A
authors.lastname: Mucientes-Molina
authors.forename: E
authors.initials: E
authors.lastname: Pedrido-Reino
authors.forename: N
authors.initials: N
authors.lastname: Lago-Rivero
authors.forename: L
authors.initials: L
authors.lastname: Constenla-Caramés
authors.forename: I
authors.initials: I
authors.lastname: Arias-Santos
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000428:Alcohol Drinking; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D003875:Drug Eruptions; D004359:Drug Therapy, Combination; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D012907:Smoking / Q000453:epidemiology; D013534:Survival; D016019:Survival Analysis
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride